70.34
0.13 (0.19%)
Market Trend
Short Term | Medium Term | ||
Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Bearish |
Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bearish | |
Stock | Prestige Consumer Healthcare In | - | - |
Stockmoo Score
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets. |
|
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Investment Style | Small Core |
52 Weeks Range | ||
Price Target Range | ||
High | 93.00 (DA Davidson, 32.22%) | Buy |
Median | 86.50 (22.97%) | |
Low | 80.00 (Canaccord Genuity, 13.73%) | Buy |
Average | 86.50 (22.97%) | |
Total | 2 Buy | |
Avg. Price @ Call | 67.23 |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
DA Davidson | 21 Jun 2024 | 93.00 (32.21%) | Buy | 69.40 |
16 May 2024 | 65.00 (-7.59%) | Hold | 64.98 | |
Canaccord Genuity | 21 May 2024 | 80.00 (13.73%) | Buy | 65.05 |
No data within this time range.
Date | Type | Details |
---|---|---|
02 Jul 2024 | Announcement | Prestige Consumer Healthcare to Release Fiscal 2025 First Quarter Earnings Results |
06 Jun 2024 | Announcement | Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference |
14 May 2024 | Announcement | Prestige Consumer Healthcare Inc. Reports Fiscal Year 2024 Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |